Biotech Values

[zipjet]

iwfal & dewophile,

I want to thank each of you for elucidating some of the issues around Cabo. I am sure I don't fully understand but at least I am now aware of some of the difficulties.

If I had the questions and understanding of iwfal, I would try and talk to one of the investigators and see if they could move my understanding forward.

My primary interest at this time is as an investor. I agree with Peter's comments on the optimistic path to approval:

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=60091563

The view I took early and still hold is that Cabo exhibits a drug effect so dramatic, so large, that there is a significant probability (over 20%) that EXEL and the FDA will find a way to move Cabo quickly into the market.

That possibility was not and still is not reflected in the stock price. The market continues to value EXEL as if Cabo will follow a relatively normal path to market.

ij